Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Microarray Test Detects Pathogenic Shifts in the Taxonomic Distribution of Vaginal Bacteria

By LabMedica International staff writers
Posted on 31 Mar 2015
A team of Italian microbiologists has developed a microarray-based diagnostic tool that monitors the vaginal bacteria population and alerts the clinician to changes in taxonomic distribution that are characteristic of bacterial vaginosis.

Under normal conditions the population of bacteria in the vagina is generally dominated by lactobacilli that confer antimicrobial protection and play a crucial role in health. More...
Bacterial vaginosis (BV) is the most prevalent lower genital tract infection in women in reproductive age and is characterized by a shift in the relative abundance of Lactobacillus spp. to greater abundance of strictly anaerobic bacteria such as Gardnerella vaginalis, Atopobium vaginae, Mycoplasma hominis, various species of Prevotella and others.

Investigators at the University of Bologna (Italy) have reported the development of a microarray based test system that they call "VaginArray". This assay was based on 17 DNA probe sets, each being specific for one of the representative bacterial species inhabiting the vaginal ecosystem. Each set was designed to be complementary to the "variable region" of the 16S rRNA of its target gene and the match must be exact in order to register as positive. The target bacteria were identified and quantified by measuring the fluorescence intensity produced by each probe set.

In practice, the entire probe set properly recognized the specific targets and showed an overall sensitivity of 6 to12 nanograms per each probe. As a practical exercise the VaginArray was applied to assess the efficacy of rifaximin vaginal tablets for the treatment of BV. The investigators analyzed the vaginal bacterial communities of 22 BV-affected women treated with 25 milligrams/day rifaximin vaginal tablets for five days. Results showed the ability of rifaximin to reduce the growth of various BV-related bacteria. Furthermore, an increase of Lactobacillus crispatus was observed in the subset of women who maintained remission after one month of therapy.

"Our microarray could be used to study alterations of the vaginal ecology associated with gynecologic disorders and to assess the impact of therapeutic agents on the vaginal microbiota," said senior author Dr. Beatrice Vitali, professor of pharmacy and biotechnology at the University of Bologna.

The paper describing VaginArray was published in the March 2, 2015, online edition of the journal Antimicrobial Agents and Chemotherapy.

Related Links:

University of Bologna



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.